A recent study by Jones et al. in The British Journal of Cancer (BJC)(Jones ME. Br J Cancer. 2016 Aug 23) estimated an almost 3 fold (2.74 times) increase risk of breast cancer among post-menopausal ...
A phase I trial was performed to determine the maximum tolerated dose (MTD), safety, pharmacokinetics and immunogenicity of the anti-EpCAM immunotoxin (IT) MOC31PE in cancer patients. An important ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results